AtriCure Future Growth
Future criteria checks 1/6
AtriCure is forecast to grow earnings and revenue by 21.5% and 13.5% per annum respectively. EPS is expected to grow by 25.2% per annum. Return on equity is forecast to be -4.4% in 3 years.
Key information
21.5%
Earnings growth rate
25.2%
EPS growth rate
Medical Equipment earnings growth | 16.4% |
Revenue growth rate | 13.5% |
Future return on equity | -4.4% |
Analyst coverage | Good |
Last updated | 17 Dec 2024 |
Recent future growth updates
US$42.67 - That's What Analysts Think AtriCure, Inc. (NASDAQ:ATRC) Is Worth After These Results
Nov 01Analysts Have Been Trimming Their AtriCure, Inc. (NASDAQ:ATRC) Price Target After Its Latest Report
Aug 02Recent updates
Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?
Dec 24A Piece Of The Puzzle Missing From AtriCure, Inc.'s (NASDAQ:ATRC) 28% Share Price Climb
Nov 06US$42.67 - That's What Analysts Think AtriCure, Inc. (NASDAQ:ATRC) Is Worth After These Results
Nov 01Is It Time To Consider Buying AtriCure, Inc. (NASDAQ:ATRC)?
Oct 31AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 43% Above Its Share Price
Oct 02Further Upside For AtriCure, Inc. (NASDAQ:ATRC) Shares Could Introduce Price Risks After 29% Bounce
Sep 06Analysts Have Been Trimming Their AtriCure, Inc. (NASDAQ:ATRC) Price Target After Its Latest Report
Aug 02AtriCure's Latest Projects And European Market Entry, Advancing Cardiac Care
Jul 25AtriCure, Inc. (NASDAQ:ATRC) Soars 26% But It's A Story Of Risk Vs Reward
Jul 18AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 88% Above Its Share Price
May 30Positive Sentiment Still Eludes AtriCure, Inc. (NASDAQ:ATRC) Following 29% Share Price Slump
Apr 04Does AtriCure (NASDAQ:ATRC) Have A Healthy Balance Sheet?
Mar 14Investors Interested In AtriCure, Inc.'s (NASDAQ:ATRC) Revenues
Jan 21Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?
Nov 29AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 99% Above Its Share Price
Sep 27Health Check: How Prudently Does AtriCure (NASDAQ:ATRC) Use Debt?
Aug 02AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Matching Investor Opinion
Jun 15Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?
Apr 14Calculating The Intrinsic Value Of AtriCure, Inc. (NASDAQ:ATRC)
Mar 02What Does AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Indicate?
Feb 09Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?
Dec 28Is Now An Opportune Moment To Examine AtriCure, Inc. (NASDAQ:ATRC)?
Sep 06An Intrinsic Calculation For AtriCure, Inc. (NASDAQ:ATRC) Suggests It's 29% Undervalued
Aug 02AtriCure: 5x Sales For A Series Of Impeding Losses? No Thanks
Jun 13Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?
Jun 08Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2027 | 719 | -22 | N/A | N/A | 1 |
12/31/2026 | 589 | -22 | 21 | 39 | 8 |
12/31/2025 | 523 | -31 | 9 | 25 | 9 |
12/31/2024 | 461 | -41 | N/A | 14 | 9 |
9/30/2024 | 448 | -39 | -1 | 10 | N/A |
6/30/2024 | 430 | -40 | -20 | -8 | N/A |
3/31/2024 | 415 | -37 | -55 | -12 | N/A |
12/31/2023 | 399 | -30 | -38 | 4 | N/A |
9/30/2023 | 381 | -25 | -43 | 1 | N/A |
6/30/2023 | 366 | -28 | -48 | -3 | N/A |
3/31/2023 | 349 | -38 | -18 | -2 | N/A |
12/31/2022 | 330 | -46 | -39 | -22 | N/A |
9/30/2022 | 316 | -56 | -37 | -22 | N/A |
6/30/2022 | 303 | 53 | -32 | -20 | N/A |
3/31/2022 | 290 | 52 | -41 | -29 | N/A |
12/31/2021 | 274 | 50 | -24 | -14 | N/A |
9/30/2021 | 259 | 45 | -18 | -10 | N/A |
6/30/2021 | 243 | -57 | -14 | -6 | N/A |
3/31/2021 | 213 | -49 | -18 | -13 | N/A |
12/31/2020 | 207 | -48 | -25 | -20 | N/A |
9/30/2020 | 210 | -46 | -36 | -27 | N/A |
6/30/2020 | 212 | -50 | -44 | -34 | N/A |
3/31/2020 | 230 | -46 | -31 | -18 | N/A |
12/31/2019 | 231 | -35 | -28 | -16 | N/A |
9/30/2019 | 222 | -23 | -20 | -11 | N/A |
6/30/2019 | 216 | -20 | -11 | -3 | N/A |
3/31/2019 | 209 | -17 | -14 | -8 | N/A |
12/31/2018 | 202 | -21 | -10 | -4 | N/A |
9/30/2018 | 195 | -20 | -10 | -4 | N/A |
6/30/2018 | 187 | -20 | N/A | -9 | N/A |
3/31/2018 | 180 | -27 | N/A | -9 | N/A |
12/31/2017 | 175 | -27 | N/A | -9 | N/A |
9/30/2017 | 170 | -33 | N/A | -10 | N/A |
6/30/2017 | 166 | -32 | N/A | -9 | N/A |
3/31/2017 | 160 | -34 | N/A | -14 | N/A |
12/31/2016 | 155 | -33 | N/A | -15 | N/A |
9/30/2016 | 150 | -36 | N/A | -20 | N/A |
6/30/2016 | 143 | -35 | N/A | -18 | N/A |
3/31/2016 | 135 | -32 | N/A | -10 | N/A |
12/31/2015 | 129 | -27 | N/A | -8 | N/A |
9/30/2015 | 123 | -22 | N/A | -6 | N/A |
6/30/2015 | 118 | -16 | N/A | -10 | N/A |
3/31/2015 | 112 | -14 | N/A | -16 | N/A |
12/31/2014 | 107 | -16 | N/A | -22 | N/A |
9/30/2014 | 99 | -16 | N/A | -23 | N/A |
6/30/2014 | 93 | -18 | N/A | -21 | N/A |
3/31/2014 | 87 | -17 | N/A | -17 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ATRC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ATRC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ATRC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ATRC's revenue (13.5% per year) is forecast to grow faster than the US market (9% per year).
High Growth Revenue: ATRC's revenue (13.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ATRC is forecast to be unprofitable in 3 years.
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/02 01:41 |
End of Day Share Price | 2024/12/31 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
AtriCure, Inc. is covered by 19 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Charley Jones | Barrington Research Associates, Inc. |
Joanne Wuensch | BMO Capital Markets U.S. (Historical) |
Michael Gorman | BTIG |